ArticlePLoS pathogens2026
TANK potentiates antiviral innate immunity by recruiting deubiquitinase USP46 to activate IKKε.
Article in PLoS pathogens, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
Abstract
IKKε plays an important role in interferon (IFN) production, however, its regulation remains poorly understood. In this study, we demonstrate that black carp TANK (bcTANK) interacts with bcIKKε and significantly enhances its activation of bcIRF3 and bcIRF7, leading to the improved antiviral activity against spring viremia of carp virus (SVCV). Mechanistically, bcTANK recruits deubiquitinase bcUSP46 to bcIKKε and leads to a reduction in polyubiquitination of and a concurrent increase in phosphorylation of bcIKKε, which suggests the activation status of this molecule. Site-directed mutagenesis revealed that lysine residues K418 and K545 of bcIKKε are critical for bcIKKε-mediated IFN production. Furthermore, we identified the SVCV phosphoprotein (P) as a viral antagonist of bcTANK/bcIKKε/bcIRF cascade. The SVCV P protein interacts with bcIKKε, promotes its polyubiquitination, attenuates its phosphorylation and disrupts its interaction with bcTANK, bcUSP46, bcIRF3, and bcIRF7, thereby facilitating viral replication. Thus, our findings reveal a novel positive regulation of IKKε by TANK.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.